Raymond James & Associates Has $1.03 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Raymond James & Associates Has $1.03 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Raymond James & Associates grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) by 34.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,331 shares of the company's stock after acquiring an additional 4,717 shares during the period. Raymond James & Associates' holdings in Intellia Therapeutics were worth $1,026,000 as of its most recent SEC filing.
Raymond James&Associates在最近提交給美國證券交易委員會的13F文件中顯示，第三季度，該公司持有的英特利亞治療公司(納斯達克：NTLA-GET評級)股票增加了34.6%。該公司持有18,331股該公司股票，在此期間又收購了4,717股。截至最近提交的美國證券交易委員會申請文件，Raymond James&Associates持有的Intellia治療公司股份價值1,026,000美元。
A number of other large investors have also recently bought and sold shares of NTLA. National Bank of Canada FI acquired a new stake in Intellia Therapeutics during the 3rd quarter worth about $39,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Intellia Therapeutics by 462.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 866 shares of the company's stock valued at $48,000 after buying an additional 712 shares during the period. Penserra Capital Management LLC acquired a new stake in shares of Intellia Therapeutics in the 1st quarter valued at about $97,000. High Net Worth Advisory Group LLC grew its stake in shares of Intellia Therapeutics by 33.3% in the 3rd quarter. High Net Worth Advisory Group LLC now owns 2,000 shares of the company's stock valued at $112,000 after buying an additional 500 shares during the period. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of Intellia Therapeutics by 10.2% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company's stock valued at $123,000 after buying an additional 220 shares during the period. 85.61% of the stock is currently owned by institutional investors and hedge funds.
其他一些大型投資者最近也買賣了NTLA的股票。加拿大國民銀行FI在第三季度收購了Intellia Treeutics的新股份，價值約3.9萬美元。中國環球資產管理有限公司在第三季度增持了英特利亞治療公司的股份462.3%。中國環球資產管理有限公司目前持有該公司866股股票，價值48,000美元，在此期間又購買了712股。Penserra Capital Management LLC在第一季度收購了Intellia治療公司的新股份，價值約97,000美元。第三季度，高淨值諮詢集團在Intellia Treeutics的股份增加了33.3%。高淨值諮詢集團現在擁有該公司2000股股票，價值11.2萬美元，在此期間又購買了500股。最後，Steward Partners Investment Consulting LLC在第二季度將其在Intellia Treeutics的股份增加了10.2%。Steward Partners Investment Consulting LLC現在擁有2368股該公司的股票，價值12.3萬美元，在此期間又購買了220股。85.61%的股票目前由機構投資者和對衝基金持有。
Insider Buying and Selling
內幕買賣
In related news, EVP Laura Sepp-Lorenzino sold 2,508 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $93,322.68. Following the sale, the executive vice president now owns 19,959 shares of the company's stock, valued at approximately $742,674.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Laura Sepp-Lorenzino sold 2,508 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $93,322.68. Following the completion of the transaction, the executive vice president now directly owns 19,959 shares in the company, valued at approximately $742,674.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Glenn Goddard sold 2,427 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total transaction of $90,308.67. Following the completion of the transaction, the chief financial officer now owns 15,404 shares of the company's stock, valued at $573,182.84. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,608 shares of company stock valued at $431,934. 3.90% of the stock is owned by company insiders.
在相關新聞中，執行副總裁Laura Sepp-Lorenzino在1月4日星期三的一筆交易中出售了2,508股Intellia治療公司的股票。這些股票的平均價格為37.21美元，總價值為93,322.68美元。出售後，執行副總裁總裁現在持有該公司19959股股票，價值約742,674.39美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可在美國證券交易委員會網站。在相關新聞中，執行副總裁Laura Sepp-Lorenzino在1月4日星期三的一筆交易中出售了2,508股Intellia治療公司的股票。這些股票的平均價格為37.21美元，總價值為93,322.68美元。交易完成後，執行副總裁總裁現在直接持有該公司19,959股股份，價值約742,674.39美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過以下方式獲取這個環節。此外，首席財務官格倫·戈達德在1月4日星期三的一筆交易中出售了2,427股Intellia治療公司的股票。這些股票的平均價格為37.21美元，總成交金額為90,308.67美元。交易完成後，首席財務官現在擁有15,404股公司股票，價值573,182.84美元。關於這次銷售的披露可以找到這裏。在上個季度，內部人士出售了11,608股公司股票，價值431,934美元。3.90%的股份由公司內部人士持有。
Analyst Ratings Changes
分析師評級發生變化
Intellia Therapeutics Trading Up 7.8 %
Intellia治療公司股價上漲7.8%
NASDAQ:NTLA opened at $41.63 on Friday. The stock has a market capitalization of $3.28 billion, a PE ratio of -7.09 and a beta of 1.93. The firm's 50 day moving average is $39.40 and its 200 day moving average is $51.99. Intellia Therapeutics, Inc. has a 12 month low of $32.44 and a 12 month high of $104.87.
納斯達克：NTLA上週五開盤報41.63美元。該股市值為32.8億美元，市盈率為-7.09，貝塔係數為1.93。該公司的50日移動均線切入位為39.40美元，200日移動均線切入位為51.99美元。Intellia Treateutics，Inc.的12個月低點為32.44美元，12個月高位為104.87美元。
Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($1.31) by ($0.18). The company had revenue of $13.27 million during the quarter, compared to the consensus estimate of $13.60 million. Intellia Therapeutics had a negative return on equity of 47.79% and a negative net margin of 859.92%. Research analysts predict that Intellia Therapeutics, Inc. will post -6.09 earnings per share for the current year.
Intellia治療公司(納斯達克代碼：NTLA-GET評級)最近一次公佈季度收益結果是在11月3日星期四。該公司公佈了該季度每股收益(1.49美元)，低於分析師普遍預期的(1.31美元)和(0.18美元)。該公司本季度的收入為1327萬美元，而市場普遍預期為1360萬美元。Intellia治療公司的淨資產回報率為負47.79%，淨利潤率為負859.92%。研究分析師預測，Intellia治療公司本年度每股收益將達到6.09美元。
About Intellia Therapeutics
關於Intellia Treateutics
(Get Rating)
(獲取評級)
Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
Intellia Treateutics，Inc.是一家臨牀階段的基因組編輯公司，致力於使用CRISPR/Cas9系統開發治療療法。它的CRISPR/Cas9系統通過生產只需一個療程就能永久編輯和/或糾正人體內疾病相關基因的療法來改變醫學，並創造出可以治療腫瘤和免疫疾病的工程細胞。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Intellia Therapeutics (NTLA)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免費獲取StockNews.com關於Intellia治療(NTLA)的研究報告
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年芯片需求回升，提振銷售觀點
- KLA公司：在動盪不安的半市場中站穩腳跟
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating).
想看看其他對衝基金持有NTLA嗎？訪問HoldingsChannel.com獲取Intellia治療公司(納斯達克代碼：NTLA-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Intellia治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Intellia治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。